Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 1990 / Article

Clinical Gastroenterology | Open Access

Volume 4 |Article ID 256258 | https://doi.org/10.1155/1990/256258

H Navert, AP Archambault, IGM Cleator, NB Hershfield, EJ Prokipchuk, ABR Thomson, "The Equivalence of Two Open Therapeutic Regimens of Cimetidine in the Treatment of Acute Duodenal Ulcer Disease: A Canadian Multicentre Trial", Canadian Journal of Gastroenterology and Hepatology, vol. 4, Article ID 256258, 5 pages, 1990. https://doi.org/10.1155/1990/256258

The Equivalence of Two Open Therapeutic Regimens of Cimetidine in the Treatment of Acute Duodenal Ulcer Disease: A Canadian Multicentre Trial

Received27 Apr 1988
Accepted07 Apr 1989

Abstract

One hundred and four patients completed a multicentre study comparing the standard cimetidine regimen of 300 mg qid with cimetidine 600 mg bid in the treatment of acute duodenal ulcer. Both dosage regimens were effective in alleviating symptoms. At the two- and four-week assessments a significantly greater decrease in frequency, duration and severity of night time pain was recorded in the 600 mg bid group (P<0.05). The healing rates were equivalent in both treatment groups. After eight weeks of treatment, 96% of the patients had healed in each treatment group. Cimetidine 600 mg bid may represent a useful alternative therapeutic regimen to the standard 300 mg qid dosage in patients with symptomatic acute duodenal ulcer disease.

Copyright © 1990 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views80
Downloads158
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.